AKT1 and cancer: Overall, these data suggest that the trametinib-resistant cell lines have bypassed the requirement for MAPK pathway signaling, and instead may rely on activated ERBB3-PI3K-AKT pathways to sustain cancer cell survival in the face of MEK inhibition.